BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,789,433 shares of the medical research company's stock, valued at approximately $5,318,092,000. BlackRock Inc. owned approximately 10.21% of Edwards Lifesciences at the end
Baxter Bros Inc. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 39,184 shares of the medical research company's stock, valued at approximately $3,545,000. A number of other large investors have
Bank Hapoalim BM purchased a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,640 shares of the medical research company's stock, valued at approximately $1,777,000. A number of other large investors
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
On August 05, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. The stock has
Glenmede Trust Co. NA trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 4.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,483 shares of the medical research company's stock after selling 6,923 shares
Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.